Benefits of Adjuvant Chemotherapy in Elderly Patients with Stage IB-IIIB Non-small Cell Lung Cancer: a Propensity-matched Analysis

Overview

Journal Transl Cancer Res

Specialty Oncology

Date 2024 Jul 11

PMID 38988934

Authors

Xuan Qin

Xiangzhi Xiao

Hongwei Xia

Ke Yang

Shengchao Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Adjuvant chemotherapy (ACT) is a well-recognized and well-established treatment for surgically resected non-small cell lung cancer (NSCLC), but its suitability for elderly patients remains controversial. Further investigation is warranted to guide ACT decisions in this demographic.

Methods: We extracted data from the Surveillance, Epidemiology, and End Results (SEER) database, focusing on patients aged 70 years or older who underwent surgical resection for stage IB, II, or III NSCLC as per the 7th edition of the American Joint Committee on Cancer staging system (AJCC 7th edition). Propensity score matching (PSM), Kaplan-Meier analysis, and Cox regression were employed for statistical analyses.

Results: There were 503 participants received ACT in this study of 2,000 patients aged 70 or older with stage IB-IIIB NSCLC who underwent surgical resection without preoperative chemotherapy. Overall, ACT did not significantly correlate with extended overall survival (OS) (P=0.07) compared to non-ACT. After 2:1 PSM, the matched cohort comprised 317 non-ACT and 206 ACT recipients. Post-PSM, the ACT group exhibited improved OS (P=0.044) compared to the non-ACT group. Cox regression analysis identified gender, primary tumor site, histologic grade, N stage, and ACT as independent predictors of OS (P<0.05). Subgroup analysis indicated amplified ACT benefits in individuals aged 70-79 years, male, with N1 stage, or those without radiotherapy.

Conclusions: ACT may confer benefits to elderly stage IB-IIIB NSCLC patients, particularly those aged 70-79 years, male, and with N1 stage.

References

Veluswamy R, Mhango G, Bonomi M, Neugut A, Hershman D, Aldridge M . Adjuvant treatment for elderly patients with early-stage lung cancer treated with limited resection. Ann Am Thorac Soc. 2013; 10(6):622-8. PMC: 5475405. DOI: 10.1513/AnnalsATS.201305-127OC. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 2.2021. J Natl Compr Canc Netw. 2021; 19(3):254-266. DOI: 10.6004/jnccn.2021.0013. View

Chida M, Minowa M, Karube Y, Eba S, Okada Y, Miyoshi S . Worsened long-term outcomes and postoperative complications in octogenarians with lung cancer following mediastinal lymph-node dissection. Interact Cardiovasc Thorac Surg. 2008; 8(1):89-92. DOI: 10.1510/icvts.2008.193383. View

Tozuka T, Noro R, Seike M, Honda K . Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of According to Evaluation of Metastatic Ability. Cancers (Basel). 2022; 14(18). PMC: 9497297. DOI: 10.3390/cancers14184363. View

OBrien M, Paz-Ares L, Marreaud S, Dafni U, Oselin K, Havel L . Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. Lancet Oncol. 2022; 23(10):1274-1286. DOI: 10.1016/S1470-2045(22)00518-6. View

Komiya T, Powell E, Guddati A . Recent trends in use of adjuvant chemotherapy in elderly stage II-III non-small cell lung cancer. Transl Lung Cancer Res. 2020; 9(4):1180-1186. PMC: 7481576. DOI: 10.21037/tlcr-19-564. View

Morgensztern D, Samson P, Waqar S, Devarakonda S, Robinson C, Govindan R . Early Mortality in Patients Undergoing Adjuvant Chemotherapy for Non-Small Cell Lung Cancer. J Thorac Oncol. 2018; 13(4):543-549. DOI: 10.1016/j.jtho.2018.01.010. View

Fruh M, Rolland E, Pignon J, Seymour L, Ding K, Tribodet H . Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. J Clin Oncol. 2008; 26(21):3573-81. DOI: 10.1200/JCO.2008.16.2727. View

Ettinger D, Wood D, Aisner D, Akerley W, Bauman J, Bharat A . Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2022; 20(5):497-530. DOI: 10.6004/jnccn.2022.0025. View

10.

Khullar O, Liu Y, Gillespie T, Higgins K, Ramalingam S, Lipscomb J . Survival After Sublobar Resection versus Lobectomy for Clinical Stage IA Lung Cancer: An Analysis from the National Cancer Data Base. J Thorac Oncol. 2015; 10(11):1625-33. PMC: 5798611. DOI: 10.1097/JTO.0000000000000664. View

11.

Ginsberg R, Rubinstein L . Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg. 1995; 60(3):615-22; discussion 622-3. DOI: 10.1016/0003-4975(95)00537-u. View

12.

Yang Z, Liu M, Yu J, Yang Y, Chen T, Han Y . Treatment of stage III non-small cell lung cancer in the era of immunotherapy: pathological complete response to neoadjuvant pembrolizumab and chemotherapy. Transl Lung Cancer Res. 2020; 9(5):2059-2073. PMC: 7653116. DOI: 10.21037/tlcr-20-896. View

13.

Ning J, Ge T, Zhu S, Han Y, Ruan S, Ma Y . The role of surgery in older patients with T1-2N0M0 small cell lung cancer: A propensity score matching analysis. Front Oncol. 2022; 12:958187. PMC: 9565197. DOI: 10.3389/fonc.2022.958187. View

14.

Szeto C, Shalata W, Yakobson A, Agbarya A . Neoadjuvant and Adjuvant Immunotherapy in Early-Stage Non-Small-Cell Lung Cancer, Past, Present, and Future. J Clin Med. 2021; 10(23). PMC: 8658154. DOI: 10.3390/jcm10235614. View

15.

Yang W, He Y, Hu Q, Peng M, Zhang Z, Xie S . Survival benefit of thermal ablation therapy for patients with stage II-III non-small cell lung cancer: A propensity-matched analysis. Front Oncol. 2022; 12:984932. PMC: 9446892. DOI: 10.3389/fonc.2022.984932. View

16.

Pathak R, Goldberg S, Canavan M, Herrin J, Hoag J, Salazar M . Association of Survival With Adjuvant Chemotherapy Among Patients With Early-Stage Non-Small Cell Lung Cancer With vs Without High-Risk Clinicopathologic Features. JAMA Oncol. 2020; 6(11):1741-1750. PMC: 7499246. DOI: 10.1001/jamaoncol.2020.4232. View

17.

Passiglia F, Bertaglia V, Reale M, Delcuratolo M, Tabbo F, Olmetto E . Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. Cancer Treat Rev. 2021; 101:102308. DOI: 10.1016/j.ctrv.2021.102308. View

18.

Chaft J, Rimner A, Weder W, Azzoli C, Kris M, Cascone T . Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer. Nat Rev Clin Oncol. 2021; 18(9):547-557. PMC: 9447511. DOI: 10.1038/s41571-021-00501-4. View

19.

Bradbury P, Sivajohanathan D, Chan A, Kulkarni S, Ung Y, Ellis P . Postoperative Adjuvant Systemic Therapy in Completely Resected Non-Small-Cell Lung Cancer: A Systematic Review. Clin Lung Cancer. 2017; 18(3):259-273.e8. DOI: 10.1016/j.cllc.2016.07.002. View

20.

Hanagiri T, Sugio K, Uramoto H, So T, Ichiki Y, Sugaya M . Gender difference as a prognostic factor in patients undergoing resection of non-small cell lung cancer. Surg Today. 2007; 37(7):546-51. DOI: 10.1007/s00595-006-3453-9. View